Last reviewed · How we verify
Piperacillin / Tazobactam Injection
Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing the antibiotic to overcome resistance.
Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing the antibiotic to overcome resistance. Used for Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and lower respiratory tract infections, Nosocomial pneumonia, Febrile neutropenia in cancer patients.
At a glance
| Generic name | Piperacillin / Tazobactam Injection |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins; bacterial beta-lactamase enzymes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is a broad-spectrum beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by bacterial beta-lactamase enzymes, extending its spectrum to include beta-lactamase-producing organisms. Together, they provide enhanced coverage against gram-positive, gram-negative, and anaerobic bacteria.
Approved indications
- Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and lower respiratory tract infections
- Nosocomial pneumonia
- Febrile neutropenia in cancer patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Phlebitis at injection site
- Headache
- Allergic reactions including anaphylaxis
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections (PHASE4)
- A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia (NA)
- Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
- Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Piperacillin / Tazobactam Injection CI brief — competitive landscape report
- Piperacillin / Tazobactam Injection updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI